Bildkälla: Stockfoto

Scibase Q3’22: Sales progress in the quarter - Redeye

Redeye continues to see a very compelling ling term investment case. Scibase's Q3 results were mixed with higher sales than expected and higher costs. We make minor adjustments to our estimates and leave our Base case unchanged at SEK 11 per share.

Redeye continues to see a very compelling ling term investment case. Scibase's Q3 results were mixed with higher sales than expected and higher costs. We make minor adjustments to our estimates and leave our Base case unchanged at SEK 11 per share.
Börsvärldens nyhetsbrev
ANNONSER